Benzinga | Oct 25, 2021 07:44AM EDT

Xeris Pharmaceuticals Enters Collaboration Agreement With Merck; Financial Terms Not Disclosed

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris' suspension-based formulation technology, XeriJect(tm), for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations. Terms of the agreement were not disclosed.